TMT1A inhibits lung adenocarcinoma progression by suppressing M2 macrophage polarization

Area of Science:

• Oncology
• Immunology
• Molecular Biology

Background:

• The role of Thiol methyltransferase 1A (TMT1A) in lung adenocarcinoma (LUAD) progression and its impact on the tumor immune microenvironment are not well understood.
• Understanding TMT1A's function is crucial for developing novel therapeutic strategies against LUAD.

Purpose of the Study:

• To investigate the role of TMT1A in LUAD progression.
• To elucidate the immunomodulatory effects of TMT1A in the LUAD microenvironment.
• To evaluate TMT1A as a potential therapeutic target for LUAD.

Main Methods:

• Analysis of clinical LUAD samples and public databases for TMT1A expression.
• Functional assays (cell proliferation, migration) to assess TMT1A's phenotypic effects.
• Single-cell transcriptome sequencing to analyze TMT1A's correlation with immune cells.
• Mechanistic studies involving macrophage polarization and PD-L1 expression.
• Co-culture experiments with LUAD cells and T cells to assess T cell activation and cytokine secretion.
• In vivo studies to validate TMT1A's effect on T cell infiltration.

Main Results:

• TMT1A expression was significantly lower in LUAD tissues compared to non-neoplastic tissues.
• TMT1A acts as an independent prognostic factor for LUAD.
• TMT1A expression inhibited LUAD cell proliferation and migration.
• TMT1A positively correlated with immune cells, particularly macrophages.
• High TMT1A expression inhibited M2 macrophage polarization and downregulated PD-L1 expression.
• TMT1A knockdown suppressed T cell activation and IFN-γ secretion.
• TMT1A expression promoted CD8+ T cell infiltration in LUAD.
• TMT1A demonstrated tumor-suppressive functions and immunomodulatory capacity.

Conclusions:

• TMT1A exhibits tumor-suppressive properties in LUAD.
• TMT1A plays a significant role in modulating the LUAD immune microenvironment.
• TMT1A is a promising therapeutic target for LUAD treatment due to its dual functions.